AusperBio Therapeutics Shows Success with AHB-137
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. have recently presented their latest findings about AHB-137, a significant advance in the treatment of chronic hepatitis B (CHB). This clinical-stage biotechnology company has focused on developing innovative oligonucleotide therapies for CHB, and their latest results demonstrate notable efficacy in patients undergoing nucleos(t)ide analogue therapy.
Key Findings from the AHB-137 Study
In a recent Phase IIa study, known as AB-10-8002, it was revealed that AHB-137 monotherapy achieved an impressive 30% functional cure rate among patients who had baseline HBsAg levels ranging from 100 to 1,000 IU/mL after 72 weeks. This research contributes significantly to the growing evidence that AHB-137 could form the backbone of future treatment strategies for HBV.
Outstanding Efficacy in Clinical Trials
The data presented from this study indicates that 30% of participants in the 225 mg and 300 mg cohorts reached the functional cure threshold (defined as HBsAg <0.05 IU/mL and HBV DNA One of the standout features of the AHB-137 treatment is its influence on viral replication post-therapy. After participants finished their AHB-137 treatment and discontinued nucleos(t)ide analogue therapy, an impressive 100% of patients remained HBV DNA-negative for a full 24 weeks. This durability in viral suppression is a critical indicator of treatment efficacy. The analysis of treatment outcomes illustrated that 89% and 82% of patients in the pooled groups maintained a complete response at Week 72, showcasing AHB-137's ability to maintain a significant reduction in both HBsAg and HBV DNA. Furthermore, the safety profile of AHB-137 is quite favorable, as it was well tolerated by patients with no serious drug-related adverse events reported. Most experienced mild to moderate side effects during the treatment phases. Professor Niu Junqi, a leading expert in the field of Hepatology, expressed the significance of these results, noting that achieving a functional cure remains a crucial target in treating chronic hepatitis B. With AHB-137 being the first therapy to reach a 30% functional cure rate in a substantial cohort, it opens doors for broader application and consideration for patients who may not achieve a full cure but could respond favorably to other treatments. Dr. Guofeng Cheng, the Co-founder and CEO of AusperBio, articulated his enthusiasm for sharing these milestone results with peers in the medical community. He highlighted that AHB-137's mechanism of action is multifaceted, targeting HBsAg reduction, suppressing viral replication, and restoring immune functionality. This positions AHB-137 as a transformational treatment option aimed at a functional cure for chronic hepatitis B. AB-10-8002, the pivotal Phase II clinical study, involved a multicenter, randomized, open-label design that assessed the safety and efficacy of AHB-137 over a 24-week monotherapy period. Patients received weekly doses of either 225 mg or 300 mg, entailing a robust protocol for follow-up and data collection. After the completion of therapy, the study emphasized continued monitoring through Week 72 to track the long-term benefits and safety of the treatment. AHB-137 represents a novel approach in antiviral treatment, conceived using AusperBio's proprietary Med-Oligo™ technology platform. Its innovative design aims to disrupt the lifecycle of hepatitis B by utilizing antisense oligonucleotides to target specific viral components. Clinical results have positioned AHB-137 as a frontrunner in the quest for achieving functional cures and transforming patient outcomes in the fight against chronic hepatitis B. As AusperBio moves forward, its commitment to advancing treatments with AHB-137 underscores the potential for groundbreaking changes in how chronic hepatitis B is managed. The company stands at the forefront of biopharmaceutical innovation, continually striving to provide patients with transformative therapeutic solutions. AHB-137 is an investigational antiviral therapy by AusperBio, developed to achieve a functional cure for chronic hepatitis B. The study demonstrated a 30% functional cure rate after 72 weeks in certain patient groups, along with excellent safety and tolerability profiles. It works by targeting HBsAg suppression, inhibiting viral DNA replication, and restoring immune function against the hepatitis B virus. The findings mark a critical advancement in hepatitis B treatment, showcasing the potential for effective therapies that are aimed at curing the infection rather than just controlling it. AusperBio plans to accelerate clinical development for AHB-137, including further Phase II studies to explore its potential in broader patient populations.Durable Viral Replication Control
Impressive Sustained Responses and Safety
Expert Commentary on the Study's Impact
Leadership Comments on Future Directions
Understanding AB-10-8002 Trials
About AHB-137
Conclusion
Frequently Asked Questions
What is AHB-137?
What were the results of the AHB-137 study?
How does AHB-137 work?
What is the significance of the findings?
What are the future plans for AHB-137?
